Pune, India -- (SBWire) -- 12/21/2017 --High-intensity focused ultrasound (HIFU) therapy is a novel, emerging, and therapeutic modality technology. It involves propagation of ultrasound waves through cancerous tissues that kills the cancer cells. HIFU is a minimal invasive technique and performed with real-time imaging by ultrasound or MRI to enable treatment targeting and monitoring. This technology have been extensively exploited for the treatment of prostate, liver, pancreatic, and bladder cancer. The American Cancer Society estimated that about 161,360 new cases of prostate cancer have been registered in the US in year 2017. Moreover, the number of people living beyond a cancer diagnosis reached were nearly 14.5 million in 2014 and is expected to rise to over 19 million by 2024. Moreover, increasing development in medical technology and its wide range of application used in the treatment of uterine fibroids, neurological disorders, cosmetic medicine, others, fuel the growth of the market. However, high cost of the therapy and its related side effects such as urinary tract infection may restrain the growth of the market.
Get a Copy of Sample Report @ https://www.marketresearchfuture.com/sample_request/885 .
Global High-Intensity Focused Ultrasound (HIFU) Therapy Market - Competitive Analysis
EDAP TMS (France), Image Guided Therapy (France), SonaCare Medical LLC (U.S.), Theraclion (France), Chongqing Haifu Medical Technology Co., Ltd (China), Koninklijke Philips N.V. (the Netherlands), Shanghai A&S Co. LTD (China), Mianyang Sonic Electronic Ltd. (China), Insightec (U.S.), Alpinion Medical Systems (Republic of Korea), and FUS Instruments (Canada) are some of the prominent players at the forefront of competition in the Global High Intensity Focused Ultrasound (HIFU) Therapy Market and are profiled in MRFR Analysis.
October, 2017- EDAP signs exclusive agreement with Theraclion to distribute Echopulse HIFU product in France. This agreement between EDAP and Theraclion will expand towards product commercialization. The companies have worked closely for years, EDAP previously licensed patents to Theraclion and will now provide significant expertise with successful market penetration through various business models in France.
July, 2017- Alpinion Medical systems launches E-CUBE 15 platinum ultrasound system. Alpinion Medical Systems had announced the launch of its new product, E-CUBE 15 Platinum. E-CUBE 15 Platinum is a high-performing diagnostic ultrasound system applied with the accumulated technologies and features developed by Alpinion which continues its efforts in developing high performance systems. Alpinion's unique imaging platform powered by new HW and SW beamforming, controls and processes the individual data of 2D and Doppler to improve Doppler performance while keeping the 2D image quality. Additionally, Optimal Image Suite Plus, the combined image optimizing tool, enhances its image processing quality and convenience with new Xpeed. It enables users to acquire optimized clinical images easily and faster. Transducers, applied with Alpinion's own single crystal technology, Crystal Signature, will provide higher resolution and superior image quality with a wide-bandwidth and higher sensitivity.
August, 2016- Siemens and INSIGHTEC signed agreement to expand access to Exablate Neuro technology.Exablate Neuro uses focused ultrasound waves to precisely target and accurately ablate tissue deep within the brain with no incisions, and while minimizing damage to adjacent healthy tissue. Siemens MR imaging plans provides patient specific treatment planning and continuous temperature monitoring for assessing treatment outcome in real-time during Exablate Neuro procedures. Exablate Neuro is the world's first and only Food and Drug Administration (FDA) approved device for the non-invasive application of MR-guided focused ultrasound to treat essential tremor and other conditions.
April, 2016- SonaCare medical announced strategic partnership with MIM, a world leader in medical imaging software. SonaCare Medical and MIM have worked together over the past year to develop cross system compatibility and deployment of the MIM Symphony fusion technology on the Sonablate prostate tissue ablation platform. This technology development allows annotated MRI data, generated by MIM Symphony, to be fused with intraoperative ultrasound images generated at the time of ablation. Incorporating this data into the ablation plan helps improve targeting regions of interest within the prostate gland during ablation.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/high-intensity-focused-ultrasound-therapy-market-885 .
Global High-Intensity Focused Ultrasound (HIFU) Therapy Market - Regional Analysis
American high intensity focused ultrasound therapy market is expecting a sound growth during the forecast period on account of increasing prevalence of the cancer including prostate, lung and breast cancer, and increasing investments in the R&D facilities for the treatment & diagnosis of cancer. National expenditure for cancer care in the US estimated about $125 billion in 2010 and could reach $156 billion by 2020. Additionally, rising healthcare expenditure and increasing awareness about the treatment are expected to fuel the market growth. On the other hand, post therapy side effects and high treatment cost may hinder the growth of the market.
Continue…
We are thankful for the support and assistance from Global High Intensity Focused Ultrasound (HIFU) Therapy Market Research Report - Forecast to 2023 chain related technical experts and marketing experts during Research Team survey and interviews.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
